Description: Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Home Page: samsungbiologics.com
300, Songdo Bio-daero
Incheon,
21987
South Korea
Phone:
82 3 2455 3114
Officers
| Name | Title |
|---|---|
| Dr. Tae-Han Kim Ph.D. | Exec. Chairman |
| Mr. John Chongbo Rim | CEO, Pres & Director |
| Mr. Dong-Joong Kim | CFO, Exec. VP, MD & Director |
| Mr. Hoyeol Yoon | Exec. VP |
| Mr. James J. Choi | Exec. VP, Chief Information & Marketing Officer and Head of Global PR |
| Mr. Doyoung Heo | VP & Head of Fin. and Investor Relations |
| Mr. Hyung Woo Moon | VP, Head of Legal Compliance & Compliance Officer |
| Mr. Yong Park | VP, CHRO & Head of HR Support Center |
| Mr. James Park | Exec. VP, MD of the Global Sales Center & CBO |
| Mr. Andy Yongsin Kim | Exec. VP & Head of Bus. Operation center |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 64.5161 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.9185 |
| Price-to-Sales TTM: | 23.4465 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |